Drugs / CT1195E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07234045 | Nov 2025 → Dec 2027 expected | precursor B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT1195E | “A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients With Relapsed/Refractory B-Cell Neoplasms” NCT07234045 ↗ |
| Modality | Cell therapy | “CT1195E CAR-T Cells Injection” NCT07234045 ↗ |